Comparison of efficacy between palonosetron-midazolam combination and palonosetron alone for prevention of postoperative nausea and vomiting in patients undergoing breast surgery and patient controlled analgesia: A prospective, randomized, double-blind study. Issue 26 (2nd July 2021)
- Record Type:
- Journal Article
- Title:
- Comparison of efficacy between palonosetron-midazolam combination and palonosetron alone for prevention of postoperative nausea and vomiting in patients undergoing breast surgery and patient controlled analgesia: A prospective, randomized, double-blind study. Issue 26 (2nd July 2021)
- Main Title:
- Comparison of efficacy between palonosetron-midazolam combination and palonosetron alone for prevention of postoperative nausea and vomiting in patients undergoing breast surgery and patient controlled analgesia
- Authors:
- Hong, Jeong-Min
Han, Yun-Hee
Lee, Dowon
Hwang, Boo Young
Baik, Jiseok
Cho, Ah Reum
Lee, Hyeon Jeong
Kim, Eunsoo - Other Names:
- Kim. Young-Kug section editor.
- Abstract:
- Abstract: Background: Postoperative nausea and vomiting (PONV) is a common complaint in patients following general anesthesia. Various antiemetics, including 5-hydroxytryptamine type 3 (5-HT3 ) receptor antagonists, are effective but still have limited efficacy. Therefore, combination therapy is preferable to using a single drug alone in high-risk patients. We performed a comparative study on the antiemetic effect of palonosetron, a 5-HT3 receptor antagonist, monotherapy vs palonosetron-midazolam combination therapy for the prevention of PONV. Methods: A total of 104 female patients scheduled for breast cancer surgery were enrolled. They were randomly divided into 2 groups, a palonosetron monotherapy group (group P) and palonosetron-midazolam combination therapy group (group PM). Both groups received 0.075 mg palonosetron intravenously after induction of anesthesia. Patient-controlled analgesia (PCA) was applied according to the allocated group. Intravenous (IV)-PCA in group P consisted of fentanyl 20 μg/kg plus normal saline (total volume: 100 ml); IV-PCA in group PM consisted of fentanyl 20 μg/kg plus midazolam 4 mg plus normal saline (total volume: 100 ml). Efficacy parameters were collected during 0 to 1, 1 to 6, 6 to 24, and 24 to 48 hours postoperative time intervals. These measures included complete response (defined as no PONV and no rescue anti-emetic use) rate, incidence of PONV, sedation score, rescue antiemetic use, rescue analgesic use, and numerical ratingAbstract: Background: Postoperative nausea and vomiting (PONV) is a common complaint in patients following general anesthesia. Various antiemetics, including 5-hydroxytryptamine type 3 (5-HT3 ) receptor antagonists, are effective but still have limited efficacy. Therefore, combination therapy is preferable to using a single drug alone in high-risk patients. We performed a comparative study on the antiemetic effect of palonosetron, a 5-HT3 receptor antagonist, monotherapy vs palonosetron-midazolam combination therapy for the prevention of PONV. Methods: A total of 104 female patients scheduled for breast cancer surgery were enrolled. They were randomly divided into 2 groups, a palonosetron monotherapy group (group P) and palonosetron-midazolam combination therapy group (group PM). Both groups received 0.075 mg palonosetron intravenously after induction of anesthesia. Patient-controlled analgesia (PCA) was applied according to the allocated group. Intravenous (IV)-PCA in group P consisted of fentanyl 20 μg/kg plus normal saline (total volume: 100 ml); IV-PCA in group PM consisted of fentanyl 20 μg/kg plus midazolam 4 mg plus normal saline (total volume: 100 ml). Efficacy parameters were collected during 0 to 1, 1 to 6, 6 to 24, and 24 to 48 hours postoperative time intervals. These measures included complete response (defined as no PONV and no rescue anti-emetic use) rate, incidence of PONV, sedation score, rescue antiemetic use, rescue analgesic use, and numerical rating scale (NRS) for pain. The complete response rate during the 0 to 24 hours interval was analyzed as the primary outcome. Results: Although the complete response rate between 0 and 24 hours was higher in group PM (42.3% and 48.1% in group P and PM, respectively), there was no statistically significant difference ( P = .55). The complete response rates in other time intervals were not different between the 2 groups as well. The sedation score and NRS score also showed no differences between the 2 groups. Conclusions: The combination therapy of palonosetron with midazolam did not lead to a greater reduction in the incidence of PONV than monotherapy in patients undergoing breast surgery and receiving IV-PCA containing fentanyl. … (more)
- Is Part Of:
- Medicine. Volume 100:Issue 26(2021)
- Journal:
- Medicine
- Issue:
- Volume 100:Issue 26(2021)
- Issue Display:
- Volume 100, Issue 26 (2021)
- Year:
- 2021
- Volume:
- 100
- Issue:
- 26
- Issue Sort Value:
- 2021-0100-0026-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-07-02
- Subjects:
- midazolam -- palonosetron -- patient-controlled analgesia -- PONV
Medicine -- Periodicals
Medicine -- Periodicals
Médecine -- Périodiques
Geneeskunde
Medicine
Periodicals
Periodicals
610.5 - Journal URLs:
- http://journals.lww.com/md-journal/pages/default.aspx ↗
http://gateway.ovid.com/ovidweb.cgi?T=JS&PAGE=toc&D=ovft&MODE=ovid&NEWS=N&AN=00002060-000000000-00000 ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/MD.0000000000026438 ↗
- Languages:
- English
- ISSNs:
- 0025-7974
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 5534.000000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 18926.xml